Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will participate in the 2023 RBC Capital Markets Global Healthcare Conference in New York City. Ying Huang, PhD, CEO of Legend Biotech, will participate in a fireside chat on Wednesday, May 17, 2023 at 9:30 a.m. (Eastern Time).

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Investor Contacts: Joanne Choi, Senior Manager, Investor Relations, Legend Biotech joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech crystal.chen@legendbiotech.com

Press Contact: Tina Carter, Corporate Communications Lead, Legend Biotech tina.carter@legendbiotech.com (908) 331-5025

Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Legend Biotech Charts.
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Legend Biotech Charts.